Chronic Liver Disease
Chronic Liver Disease is a progressive condition where ongoing inflammation and destruction of liver cells lead to fibrosis and scarring (cirrhosis) over a period longer than six months, potentially encompassing a range of liver pathologies such as inflammation, cirrhosis, and hepatocellular carcinoma.
Health Outcomes
- Absence of Microbial Translocation
- Alleviated Liver Injury
- Alleviated Organ Injury
- Altered Amino Acid Metabolism
- Altered Bile Acid Composition
- Altered Fatty Acid Profiles
- Altered Plasma Metabolite Levels
- Altered Pro-Inflammatory Cytokine Levels
- Changed Albumin Level
- Decreased Immune Response to Influenza Vaccination
- Decreased Serum IgM Levels at 60 Days
- Elevated Acetic Acid Levels
- Elevated Alkaline Phosphatase Levels
- Elevated Bile Acid Levels
- Elevated Ferric Iron Levels
- Elevated IL-6 Levels
- Elevated Malondialdehyde Levels
- Elevated Serum Alanine Aminotransferase Levels
- Elevated Serum Globulin Levels
- Enhanced Alkaline Phosphatase Activity
- Enhanced Antioxidant Defense
- Enhanced Antioxidant Enzyme Activity
- Enhanced Antioxidant Levels
- Enhanced Antioxidant Metabolism
- Enhanced Bile Salt Resistance
- Enhanced Immune Evasion
- Enhanced Liver Protection
- Enhanced Viability in Bile Conditions
- Extended Lifespan
- Improved Alcohol-Associated Liver Disease Parameters
- Improved Alcohol-induced Liver Injury
- Improved Antioxidant Enzyme Levels
- Improved Apparent Digestibility of Crude Protein
- Improved Blood Chemistry
- Improved Cell-Cell Signalling
- Improved Child-Pugh Score
- Improved Child-Pugh Scores
- Improved Clearance Efficiency
- Improved Detoxification
- Improved Endotoxemia-related Inflammation
- Improved Energy Availability
- Improved Enteral Nutrition
- Improved Fibrosis
- Improved Growth in Bile-Containing Medium
- Improved Hepatic Damage
- Improved Hepatic Disease
- Improved Hepatic Function
- Improved Histopathological Protection
- Improved Iron Levels
- Improved Liver Biomarkers
- Improved Liver Disease Biomarkers
- Improved Liver Enzyme Activity
- Improved Liver Fatty Acid Composition
- Improved Liver Function (γ-glutamyltranspeptidase)
- Improved Liver Health
- Improved Liver Metabolic Pathways
- Improved Liver Morphology
- Improved Minimal Hepatic Encephalopathy
- Improved NAFLD
- Improved Organ Histology
- Improved Parent/Caregiver Health-Related Quality of Life
- Improved Phagocytic Function
- Improved Protein Utilization
- Improved Redox Homeostasis
- Improved Serum Biochemical Catalase Levels
- Improved Serum Biochemistry
- Improved Serum Protein Homeostasis
- Improved Serum Protein Status
- Improved Survival Through Digestive Tract
- Improved Symptoms of Chronic Condition
- Improved Tolerance to Bile Salts
- Improved Vaccine Efficacy
- Incidence of Death
- Increase in Persistent Diseased Sites
- Increased Antiapoptotic Activity
- Increased Aspartate Aminotransferase Concentration
- Increased Aspartate Aminotransferase Level
- Increased Aspartate Transferase Level
- Increased Bacterial Translocation
- Increased Betaine Content
- Increased Bile Salt Tolerance
- Increased Branched-Chain Fatty Acids Concentration
- Increased Catalase Levels
- Increased Circulating Bile Acid Levels
- Increased Conjugated Bile Acid Levels
- Increased Degradation of Non-Assimilated Compounds
- Increased Fecal Bile Acid Levels
- Increased Fecal Excretion of Aflatoxin B1
- Increased Ferritin Level
- Increased Hepatic Antioxidant Enzyme Levels
- Increased Histological Damage
- Increased Hydroxy Fatty Acid Level
- Increased IgM Concentration
- Increased Liver Alcohol Metabolizing Enzyme Activity
- Increased Liver Enzyme Levels
- Increased NK Cell Count
- Increased Number of Persistent Diseased Sites
- Increased Occurrence of Serious Adverse Events
- Increased Organ Weights
- Increased PT/INR
- Increased Parabenzoylaminobenzoic Acid Concentration
- Increased Plasma Deconjugated Bile Acids
- Increased Plasma GLDH
- Increased Production of Acetate
- Increased Proteolysis
- Increased Reactive Oxygen Species Production
- Increased Retinol Level
- Increased Serum Antioxidant Enzyme Levels
- Increased Serum Ferritin Level
- Increased Serum NAD+ Levels
- Increased Serum Peroxidase Activity
- Increased Serum Protein Levels
- Increased Serum Total Bile Acid Levels
- Increased Serum Triglycerides
- Increased Survival Rate During Candidiasis
- Increased Susceptibility to Salmonella Infection
- Increased Total Bile Acid Levels
- Increased Total Bile Acids
- Increased Total Body Iron Level
- Increased Unconjugated Bile Acid Levels
- Increased Unconjugated Bile Acids
- Increased Vitamin B12 Level
- Increased Vitamin B12 Levels
- Inhibited Activation of Apoptotic Biomarkers
- Liver Protection from Aflatoxin B1 Damage
- Maintained Safety with Repeated Oral Exposure
- Maintenance of NK Cell Activity
- Modified Hepatic Inflammatory Cell Pattern
- Modulated Bile Acid Profile in Ileum
- Multiorgan Failure
- No Change in Fibrosis
- No Cytochrome P450 Induction
- No Illness or Death Despite Bacterial Translocation
- No Significant Change in Aflatoxin Distribution or Metabolism
- Normalized INR
- Potential Modulation of FGF-19 Levels
- Preserved Liver Structure
- Prevented Liver Injury
- Prolonged INR
- Reduced ALT Levels
- Reduced Abnormal Increase in Bilirubin
- Reduced Acute Pancreatitis Severity
- Reduced Alanine Aminotransferase Level
- Reduced Alcohol Consumption
- Reduced Alpha-1-Antitrypsin Level
- Reduced Aminotransferase Level
- Reduced Ammonia Excretion
- Reduced Anaerobic Gram-Negative Bacterial Counts
- Reduced Anthropometric Parameters
- Reduced Anticoagulation / Increased Warfarin Variability
- Reduced Apolipoprotein B Level
- Reduced Appetite Loss Incidence
- Reduced Aspartate Aminotransferase Levels
- Reduced Aspartate Transaminase Activity
- Reduced Average Daily Gain
- Reduced Bacterial Translocation
- Reduced Bile Acid Levels
- Reduced Bile Acid Synthesis
- Reduced Blood Ammonia Level
- Reduced Butyrylcholinesterase Activity
- Reduced Cell Growth Rate
- Reduced Cholic Acid Level
- Reduced Chronic Consumption Toxicity
- Reduced Clonorchiasis Severity
- Reduced Cumulative Morbidity Rates
- Reduced Cumulative Mortality from Vibrio vulnificus
- Reduced Cytotoxicity
- Reduced D-Dimer Level
- Reduced Dimethyl Sulfide Level
- Reduced Drug Concentration
- Reduced Edema
- Reduced Elevated Liver Enzymes
- Reduced Elevated Serum Alanine Aminotransferase (ALT)
- Reduced Endoplasmic Reticulum Stress Markers
- Reduced Endotoxin Levels
- Reduced Energy Intake
- Reduced Fasting Conjugated Bile Acids
- Reduced Fat Weight
- Reduced Fecal Secondary Bile Acid Contents
- Reduced Fibrinogen Level
- Reduced Fibrosis Marker Levels
- Reduced Free Triiodothyronine
- Reduced Fresh Frozen Plasma Transfusion
- Reduced Fumonisin B1 Levels
- Reduced Globulin Level
- Reduced Glucuronide Metabolite Level
- Reduced Glutathione Redox Ratio
- Reduced Growth Performance
- Reduced Hematocrit Level
- Reduced Hepatic CML Absorption
- Reduced Hepatic Encephalopathy
- Reduced Hepatic Inflammation and Oxidative Stress
- Reduced Hepatic Lipid Synthesis
- Reduced Hepatic Steatosis Severity
- Reduced Hepatic Stellate Cell Activation
- Reduced Hepatocellular Carcinoma Recurrence
- Reduced Hepatocellular Damage
- Reduced Hepatocyte Necrosis
- Reduced Histological Damage
- Reduced Histological Damage Scores
- Reduced Histological Liver Injury
- Reduced Histological Scores
- Reduced Incidence of Abnormal Increase in Alkaline Phosphatase
- Reduced Incidence of Liver Cancer
- Reduced Incidence of Pyogenic Liver Abscess
- Reduced Isoleucine Level
- Reduced Lathosterol to Total Cholesterol Ratio
- Reduced Lipid Peroxidation
- Reduced Liver Cholesterol
- Reduced Liver Damage
- Reduced Liver Disease Progression
- Reduced Liver Disease Symptoms
- Reduced Liver Fat Vacuoles
- Reduced Liver Fibrosis
- Reduced Liver Inflammation Fibrosis Score
- Reduced Liver Injury Marker
- Reduced Liver Lesion Severity
- Reduced Liver Lipid Accumulation
- Reduced Liver Oxidative Stress Injury
- Reduced Liver Size
- Reduced Liver Stiffness
- Reduced Liver Weight-to-Body Weight Ratio
- Reduced Malonaldehyde Levels
- Reduced Microbial Translocation to the Liver
- Reduced Mortality from Influenza Infection
- Reduced Muscle Protein Breakdown
- Reduced NAFLD Activity Score
- Reduced NASH Activity
- Reduced Nuclear Factor Kappa B Activation
- Reduced Organ Damage
- Reduced Organ Weight
- Reduced Oxidative Tissue Injury
- Reduced Physiological Impairments
- Reduced Plasma Endotoxin Concentration
- Reduced Plasma Malondialdehyde Levels
- Reduced Procollagen Type 1 N-terminal Propeptide Level
- Reduced Proinflammatory Bacteria
- Reduced Pulsatility Index
- Reduced Ruminococcus Abundance
- Reduced Salmonella Translocation to Liver
- Reduced Serpin Level
- Reduced Serum Albumin Levels
- Reduced Serum Creatinine Levels
- Reduced Serum D-Lactate Levels
- Reduced Serum Gamma Glutamine Transaminase Levels
- Reduced Serum Haptoglobin Concentration
- Reduced Serum Osteocalcin Levels
- Reduced Serum Transaminase Levels
- Reduced Serum α-1-Acid Glycoprotein Levels
- Reduced Significant Weight Loss
- Reduced Sitosterol Level
- Reduced Steatohepatitis
- Reduced Thiobarbituric Acid-Reactive Substance Levels
- Reduced Total Triiodothyronine
- Reduced Triiodothyronine Level
- Reduced Urea Level
- Reduced Urinary p-Cresol Excretion
- Reduced Vitamin E Level
- Regenerated Hepatic Tissue
- Regulated Liver Glycerophospholipid Metabolism
- Regulated Microbial Metabolism
- Resolved Keratomalacia
- Slower Weight Gain
- Stabilized Fecal Secondary Bile Acids
- Stable Alanine Aminotransferase Levels
- Stable Aspartate Aminotransferase Levels
- Suppressed PPAR/SREBP Pathway Gene Activity
- Tolerance of Probiotic in Immunocompromised Individuals
- Unchanged Body Composition
- Unchanged Total Cholesterol